SGLT1, short for sodium-glucose cotransporter 1, is a protein embedded in cell membranes that pulls glucose and galactose into cells by hitching them to sodium ions moving down their concentration gradient. It is most famous for its role in the small intestine, where it handles the bulk of dietary glucose absorption, but it also shows up in the kidneys, heart, brain, and several other tissues. The protein sits at a surprising number of biological crossroads, from the chemistry behind oral rehydration solutions to the secretion of gut hormones that regulate blood sugar after a meal.
How SGLT1 Moves Sugar Across a Membrane
SGLT1 is not a simple doorway. It is an active transporter that uses energy stored in the sodium gradient across a cell membrane to drag sugar molecules into the cell against their own concentration gradient. The cell keeps sodium levels low inside by continuously pumping sodium out through another protein (the sodium-potassium ATPase). SGLT1 exploits that imbalance: when sodium ions rush back into the cell through SGLT1, they bring glucose or galactose along for the ride. The coupling ratio is two sodium ions for every one sugar molecule, which gives SGLT1 enough energy to concentrate sugar inside the cell well above the level on the outside.1Biomedicine & Pharmacotherapy. Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review This 2:1 sodium-to-sugar stoichiometry is one of the defining characteristics that sets SGLT1 apart from its sibling transporter, SGLT2.
The protein itself is thought to have arisen through an ancient gene duplication event. The human SGLT1 gene spans about 72 kilobases and contains 15 exons, and comparison of its structure with its predicted protein shape suggests it may have evolved from a simpler six-membrane-spanning ancestor that doubled itself.2PubMed. Structure of the human Na+/glucose cotransporter gene SGLT1 That evolutionary history helps explain why SGLT-family proteins are found across a wide range of organisms, from bacteria to mammals.
Where SGLT1 Shows Up in the Body
The two best-studied locations for SGLT1 are the lining of the small intestine and the late segments of the kidney’s proximal tubule. In the intestine, the protein sits on the brush-border surface of absorptive cells, facing the contents of the gut. In the kidney, it occupies a downstream stretch of the tubule (the S3 segment), mopping up glucose that the higher-capacity SGLT2 transporter missed farther upstream.3PubMed. Intestinal SGLT1 in metabolic health and disease
But SGLT1 is far from a two-tissue protein. Its messenger RNA has been detected in the heart, skeletal muscle, liver, lung, trachea, brain, pancreatic alpha cells, salivary glands, prostate, testes, cervix, stomach, colon, and mesenteric fat. Confirmed protein expression beyond the gut and kidney includes the heart, lung, liver, skeletal muscle, salivary glands, and pancreatic alpha cells.4PubMed Central. Sodium–glucose cotransporters: Functional properties and pharmaceutical potential SGLTs as a therapeutic target What it does in many of those tissues is still being worked out, but in a few of them, researchers have found genuinely interesting functional roles, as we will see in later sections.
The Gut’s Primary Glucose Gateway
SGLT1’s best-understood job is absorbing glucose and galactose from digested food. When you eat a meal containing starch or table sugar, digestive enzymes break the carbohydrates down into simple sugars in the gut lumen. SGLT1 on the brush border of intestinal cells then grabs those sugars and pulls them inside, powered by the sodium gradient that the sodium-potassium pump maintains on the opposite side of the cell.
Experiments in mice engineered to lack SGLT1 put the transporter’s importance in sharp relief. Those animals developed severe diarrhea from glucose and galactose sitting unabsorbed in the gut but thrived on a diet free of those sugars.5PubMed Central. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion In a separate study using radioactively labeled glucose, animals without SGLT1 absorbed roughly 80 percent less glucose tracer from the intestine, and their blood levels of the tracer dropped by about 73 percent compared with normal mice.6PLoS ONE. The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing There has been debate about whether a second transporter called GLUT2 can step in at high sugar concentrations to supplement SGLT1, but the knockout data consistently show that SGLT1 is the dominant route regardless of glucose load.
How SGLT1 Differs From SGLT2
SGLT2 gets more public attention because blockbuster diabetes drugs (empagliflozin, dapagliflozin, and others) work by inhibiting it. But the two transporters have distinct personalities. SGLT2 sits in the early segments (S1 and S2) of the kidney’s proximal tubule, has low affinity for glucose but high capacity, and uses a 1:1 sodium-to-glucose ratio. SGLT1, by contrast, has high affinity but low capacity and uses a 2:1 ratio.1Biomedicine & Pharmacotherapy. Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: An analytic review Think of SGLT2 as a wide, fast conveyor belt that reclaims most filtered glucose early, and SGLT1 as a precise scavenger that catches the remaining glucose further along the tubule.
Another important difference is sugar selectivity. Biophysical studies showed that SGLT2 excludes galactose, while SGLT1 happily transports both glucose and galactose. The apparent affinity of SGLT2 for a glucose analog was roughly an order of magnitude lower than SGLT1’s, and the sodium cooperativity (reflected in a Hill coefficient of 1 for SGLT2 versus 2 for SGLT1) matches the different coupling ratios. Modeling suggests that many of SGLT2’s kinetic properties can be predicted simply by reducing sodium coupling from two ions to one.7PubMed. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2
In the kidney, the two transporters work in tandem. SGLT2 reabsorbs the majority of filtered glucose, and SGLT1 handles most of the remainder. Knocking out either transporter in mice causes glucose to spill into the urine.8PubMed Central. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2 This is why SGLT2 inhibitors cause mild glucose loss in the urine as their therapeutic mechanism, and it is also why dual inhibitors that hit both SGLT1 and SGLT2 push that glucose loss a bit further.
SGLT1 and the Incretin Hormones
Beyond simply absorbing sugar, SGLT1 plays a role in telling the rest of the body that sugar has arrived. When glucose enters intestinal cells through SGLT1, nearby enteroendocrine cells release hormones called incretins, primarily GLP-1 and GIP. These hormones travel through the bloodstream to the pancreas, where they amplify insulin release and help keep blood sugar in check after a meal.
Studies using human intestinal tissue showed that blocking SGLT1 with the inhibitor phlorizin shut down glucose-stimulated GLP-1 secretion. Even a non-metabolizable sugar that SGLT1 can transport was enough to trigger GLP-1 release, and removing sodium from the solution, which halts SGLT1 activity, blocked the response entirely.9PubMed Central. Signal Transduction Mechanisms Controlling Glucose-Induced GLP-1 Secretion in Human Small Intestine The evidence is clear: SGLT1 is not just a sugar shuttle; it is a sensor that triggers hormonal signals coordinating the body’s response to incoming nutrients.
This link has practical consequences. In patients who have undergone gastric bypass surgery, where food reaches the small intestine faster than normal, blocking SGLT1 with canagliflozin reduced the early spike in GLP-1 by about 28 percent and the peak of GIP by roughly 57 percent.10Diabetes. 1971-P: SGLT1-Mediated Glucose Absorption Is Important for Incretin Hormone Secretion after Gastric Bypass Surgery That finding matters because part of the metabolic benefit of gastric bypass is thought to come from enhanced incretin secretion, and it hints that SGLT1-mediated absorption is a key trigger.
The Oral Rehydration Connection
One of the most consequential practical applications of SGLT1 knowledge has nothing to do with diabetes. Oral rehydration solutions (ORS), which have saved millions of lives from diarrheal diseases, work because of this transporter. When someone with severe diarrhea drinks a solution containing both sodium and glucose, SGLT1 co-transports both into the intestinal cells. Water follows by osmosis. Without both sodium and glucose present to activate the transporter, the intestine cannot pull water back efficiently.
Research on ORS formulations has confirmed that both sodium and glucose are essential for activating SGLT1’s pro-absorptive effect, and that the ratio between them is critical for maximizing fluid absorption.11PubMed Central. Potency of Oral Rehydration Solution in Inducing Fluid Absorption is Related to Glucose Concentration Too much glucose without enough sodium, or vice versa, diminishes the transport rate. The WHO’s ORS formulation was designed around this physiology, and it remains one of the most cost-effective medical interventions in global health.
SGLT1 in the Heart
The discovery of SGLT1 in heart muscle was initially surprising because the heart was thought to rely almost exclusively on GLUT-family transporters for glucose. But SGLT1 protein has been confirmed in the sarcolemma (outer membrane) of cardiac muscle cells in both humans and mice.12PubMed Central. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states And its expression does not stay static: in both type 2 diabetes and ischemic heart disease, SGLT1 levels in the heart increase two- to three-fold.
Immunohistochemical studies of human autopsy hearts confirmed that SGLT1 is expressed throughout the organ. Functional experiments showed that blocking SGLTs with phlorizin during ischemia-reperfusion injury in mice worsened the damage, increasing infarct size and impairing recovery of heart function. The interpretation is that when the heart is starved of blood flow and then reperfused, SGLT1 helps maintain glucose uptake for emergency energy production, and blocking it at that moment is harmful.13PLoS ONE. Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice
In a genetic mouse model of cardiac glycogen storage disease, SGLT1 expression in the heart was elevated five- to seven-fold, and blocking SGLT1 with phlorizin reduced cardiac glucose uptake by about 40 percent in these animals. The upregulation was driven by increased activity of an energy-sensing enzyme called AMPK, which boosted SGLT1 gene expression roughly three-fold in normal mice when activated.14PubMed Central. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy The picture that emerges is that SGLT1 acts as a backup glucose supply line for the heart, one that gets turned up when the heart is stressed or diseased.
Brain Glucose Sensing
SGLT1 also appears in the brain, where it may contribute to something quite different from bulk sugar transport: glucose sensing. Specialized neurons in the hypothalamus monitor blood sugar levels and adjust feeding behavior and hormone release accordingly. Some of these “glucose-excited” neurons increase their firing rate when glucose rises.
Researchers found that a non-metabolizable sugar substrate of SGLT (alpha-methylglucopyranoside) mimicked the effect of high glucose in about two-thirds of glucose-excited neurons, and both the glucose and the SGLT substrate responses were blocked by removing sodium or by adding the SGLT inhibitor phlorizin. SGLT1 mRNA was detected in both cultured neurons and adult rat hypothalamic tissue.15PubMed Central. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing The implication is that at least some hypothalamic neurons use SGLT1 not just for fueling themselves but as part of their glucose-detection machinery. SGLT1’s proposed roles in the brain also extend to energy supply, regulation of whole-body glucose balance, and possibly learning and memory, though much of this remains at the early research stage.16PubMed Central. Glucose transporters in brain in health and disease
What Happens When SGLT1 Is Missing
Loss-of-function mutations in the gene encoding SGLT1 (called SLC5A1) cause a rare condition known as glucose-galactose malabsorption, or GGM. Affected infants develop severe, life-threatening diarrhea within the first days of life because glucose and galactose accumulate unabsorbed in the intestine, drawing water into the gut by osmosis.17PubMed. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption The condition is autosomal recessive, meaning a child must inherit a defective copy of the gene from each parent.18PubMed Central. SLC5A1 Variants in Turkish Patients with Congenital Glucose-Galactose Malabsorption
If GGM is not recognized early, it can be fatal. But if glucose and galactose are removed from the diet and replaced with fructose-based formulas (fructose uses a different transporter, GLUT5), affected children can survive and develop normally.19PubMed Central. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk The rarity of GGM has made it hard to study in large numbers, but the cases that have been characterized involve dozens of distinct mutations scattered across the SGLT1 gene, some disrupting the protein’s folding, others blocking its trafficking to the cell surface.
Diet, Exercise, and SGLT1 Regulation
SGLT1 is not fixed in quantity. The intestine adjusts how much of it lines the brush border based on dietary patterns, which has practical implications for both athletes and everyday nutrition. A high-carbohydrate diet increases the density of SGLT1 transporters in the intestinal lining and boosts the transporter’s activity, allowing greater carbohydrate absorption and oxidation during exercise.20PubMed Central. Training the Gut for Athletes
In one study, rats fed a high-carbohydrate diet had significantly higher SGLT1 protein levels in the brush-border membrane of the jejunum compared with animals on a moderate-carbohydrate diet.21PubMed Central. High Carbohydrate Diet Increased Glucose Transporter Protein Levels in Jejunum but Did Not Lead to Enhanced Post-Exercise Skeletal Muscle Glycogen Recovery Research in mice has traced part of this regulation to epigenetic changes: a high carbohydrate-to-fat ratio in the diet enhanced a specific chemical modification on the SGLT1 gene’s associated histone proteins, which in turn ramped up gene expression.22PubMed. Inductions of histone H3 acetylation at lysine 9 on SGLT1 gene and its expression by feeding mice a high carbohydrate/fat ratio diet
For endurance athletes, this is relevant because the intestine can become a bottleneck during long events. If carbohydrate arrives faster than the gut can absorb it, the result is GI distress, cramping, and poor fueling. Sports nutrition researchers now recommend that athletes “train the gut” by gradually increasing carbohydrate intake during training, which upregulates SGLT1 and other transporters, expanding the gut’s absorptive capacity for race day.
Drugs That Target SGLT1
The success of SGLT2 inhibitors in treating diabetes and heart failure naturally led researchers to ask whether adding SGLT1 inhibition could offer additional benefits. The most advanced drug with meaningful SGLT1 activity is sotagliflozin, a dual SGLT1/SGLT2 inhibitor. By blocking SGLT1 in the gut, sotagliflozin delays intestinal glucose absorption, blunting the post-meal blood sugar spike. By blocking SGLT2 in the kidney, it increases urinary glucose excretion. Randomized trials have shown that sotagliflozin significantly lowers the risk of major cardiovascular events, heart failure hospitalizations, and death in patients with and without diabetes.23PubMed Central. Dual SGLT1/2 inhibition with sotagliflozin: a pharmaceutical breakthrough in heart failure management and cardiometabolic risk reduction
Other dual inhibitors are in development. One experimental compound, JP-2266, showed even greater potency against SGLT1 than sotagliflozin in laboratory assays.24Diabetes. Antidiabetic Effect of JP-2266, a Novel SGLT1/2 Dual Inhibitor, for the Treatment of Type 1 Diabetes The therapeutic logic is that layering intestinal SGLT1 blockade on top of renal SGLT2 blockade might produce better overall blood sugar control and stronger cardiovascular protection than either alone.
There are downsides to hitting SGLT1 with drugs. Because the transporter is the gut’s main glucose and galactose gateway, blocking it can cause diarrhea, the same symptom seen in genetic glucose-galactose malabsorption. There are also concerns about volume depletion, interference with oral treatment of low blood sugar episodes (since glucose absorption itself is slowed), and a possible increased risk of euglycemic diabetic ketoacidosis.25PubMed. SGLT1 inhibition: Pros and cons These risks tend to be manageable in clinical practice, but they illustrate why selectively inhibiting SGLT1 requires more caution than targeting SGLT2 alone.
SGLT1 in Cancer and Sugar Taste Sensing
Researchers have found SGLT1 overexpressed in certain cancers, particularly HER2-positive breast cancer. In that context, elevated SGLT1 appears to feed tumor cell proliferation by activating a well-known cell-survival signaling pathway, and knocking down SGLT1 in lab experiments blocked that pathway and slowed cell growth. Higher SGLT1 expression in tumors was also associated with lymph node metastasis and shorter patient survival.26PubMed Central. Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer Whether SGLT1 could eventually serve as a drug target in oncology remains speculative, but the findings make biological sense: cancer cells are voracious glucose consumers, and any transporter that feeds their sugar habit could be exploited.
At the opposite end of the body, SGLT1 has been implicated in sugar taste perception. Behavioral experiments in mice showed that blocking SGLT1 with phlorizin reduced the number of licks and the amount of glucose solution the animals consumed, suggesting the transporter contributes to how the tongue senses sweetness or at least to the rewarding properties of sugar.27PubMed Central. Sodium-glucose cotransporter 1 as a sugar taste sensor in mouse tongue This is still early-stage work, but it adds yet another dimension to a protein that most people, if they have heard of it at all, associate only with the gut.
Metformin and the Gut Microbiome Connection
Metformin, the world’s most widely prescribed diabetes drug, may partly work through SGLT1 in ways that were not appreciated until recently. In rats fed a high-fat diet, metformin delivered directly to the upper small intestine shifted the gut microbiome, increasing the abundance of Lactobacillus species. These microbial changes occurred under the same conditions that restored SGLT1 expression in the intestinal lining, leading researchers to propose that metformin’s glucose-lowering effect in the gut depends, at least partly, on an SGLT1-mediated glucose-sensing pathway shaped by the local microbiome.28Cell Metabolism. Metformin Restores Glucose Homeostasis through an SGLT1-Dependent Glucoregulatory Pathway in the Upper Small Intestine
This is one of those findings that reframes something familiar. Metformin has been used since the 1950s, and its full mechanism of action is still debated. The idea that one of its paths runs through SGLT1 and the bacteria living in the upper gut adds a layer of complexity, but also a potential explanation for why metformin causes gastrointestinal side effects in so many patients: it may be altering the very transporter and microbial community that manage sugar absorption in the small intestine.